A SPECIALTY LIFE
SCIENCES COMPANY
Corporate Presentation
OCTOBER 2021
US: FRANKFURT:
RVVTF 31R
Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: mfrank@revivethera.com
FORWARD LOOKING STATEMENTS
Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "intend", "estimate", "predict", "potential", "continue" or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.
© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. | 2 |
REVIVE THERAPEUTICS
Specialty life sciences company | FDA approved Phase 3 clinical | Developing novel Psilocybin |
focused on repurposing drugs | trial for Bucillamine in the | and Cannabidiol therapeutics |
for rare disorders and | treatment of COVID-19 | for various CNS and |
infectious diseases | inflammatory disorders |
Robust patent portfolio | Near-team value creation |
covering methods and | milestones |
compositions of drugs |
Bucillamine
Psilocybin
Cannabidiol
© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. | 3 |
PHARMACEUTICAL STRATEGY
Clinical development of | Targeting Rare | Novel Uses, | Targeting FDA | |||
Psilocybin, Cannabidiol | Disorders and | Formulations, and | Designations: | |||
and Bucillamine | Infectious Diseases, | Delivery System | Orphan, Fast track, | |||
Neurological Disorders, | Breakthrough | |||||
Mental Health and | therapy | |||||
Liver Diseases | ||||||
© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. | 4 |
PATENT PORTFOLIO
Title | USPTO No. | Status |
Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 | 62/991,996 | Provisional patent filed |
Use of Bucillamine in the Treatment of Gout | US9662305 | Issued on May 30, 2017 |
Drug Delivery System | US 8642088 | Issued on February 4, 2014 |
US 9545423 | Issued on January 17, 2017 | |
US 10104888 | Issued on October 23, 2018 | |
Psilocybin effervescent and psilocybin tablet - Solid Oral Pharmaceutical Compositions | 62/985,052 | Provisional patent filed |
Psilocybin hard-shell capsules - Pharmaceutical Capsule Compositions | 62/985,070 | Provisional patent filed |
Psilocybin gum drops - Pharmaceutical Gumdrop Compositions | 62/985,084 | Provisional patent filed |
Psilocybin oral strips and transmucosal - Thin-Film Pharmaceutical Delivery System and Formulations | 62/985,098 | Provisional patent filed |
Psilocybin - Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration | 62/984,590 | Provisional patent filed |
Methods for the Extraction and Crystallization of Psilocybin | 62/985,360 | Provisional patent filed |
Psilocybin in the Treatment of Neurological Brain Injury | 63/011,493 | Provisional patent filed |
Use of Psilocybin in the Treatment of Cancer | 63/133,913 | Provisional patent filed |
Psilocybin Pharmaceutical Combination Therapies | 63/125,106 | Provisional patent filed |
Use of Cannabidiol in the Treatment of Autoimmune Hepatitis | US 8242178 | Issued on August 14, 2012 |
© COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Revive Therapeutics Ltd. published this content on 06 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 October 2021 18:35:06 UTC.